Ireland· IE-PA-PA1353/005/001
Embesin 20 IU/ml concentrate for solution for infusion
A vasopressin (argipressin) product containing argipressin, registered in Ireland by Orpha-Devel Handels und Vertriebs GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Vasopressin (argipressin) is registered in 10 of 19 countries.
Countries holding a registration under ATC H01BA01 (vasopressin (argipressin)), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 6 of them publish a price we can compare per daily dose
Vasopressin (argipressin) · ATC H01BA01
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Argipressin
- Manufacturer
- Orpha-Devel Handels und Vertriebs GmbH
- Country
- Ireland (IE)
- ATC code
- H01BA01
- ATC class
- Vasopressin (argipressin)
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA1353/005/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
166 interactions on record for vasopressin (argipressin).
Graded by severity as the source publishes them — 39 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vasopressin (argipressin) · interactions on record
166 records
- 39 severe
- 125 moderate
- 2 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vasopressin (argipressin) in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandEmpressinOrpha-Devel Handels und Vertriebs GmbH
- SwedenEmbesin 40 IE/2 ml Koncentrat till infusionsvätska, lösningOrifarm AB
- BelgiumReverpleg 40 IU/2 mlOrpha-Devel Handels und Vertriebs
- NorwayEmpressinOrpha-Devel Handels und Vertriebs GmbH
- PolandEmpesinOrpha-Devel Handels und Vertriebs GmbH
- United StatesvasopressinAmneal Pharmaceuticals LLC
- United KingdomArgipressin 20units/1ml solution for injection ampoulesVantage Pharmaceuticals Ltd
- CanadaVASOPRESSIN INJECTION USPSANDOZ CANADA INCORPORATED
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Empesin
- Belgium · Reverpleg
- Bulgaria · Емпресин
- Czechia · Embesin
- Germany · Argipressin Farmak, Empressin
- Denmark · Empressin
- Estonia · Empesin
- Spain · Empressin
- Finland · Empressin
- France · Reverpleg
- United Kingdom (Northern Ireland) · Argipressin Aop, Argipressin Mercury Pharmaceuticals
- Greece · Empressin
- Croatia · Empressin
- Hungary · Embesyn
- Italy · Empressin
- Lithuania · Empesin
- Luxembourg · Reverpleg
- Latvia · Empesin
- Netherlands · Empressine
- Norway · Empressin
- Poland · Argipressin Farmak, Empesin
- Portugal · Empressin
- Romania · Reverpleg
- Sweden · Empressin
- Slovenia · Empesin
- Slovakia · Embesin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/de815218-1776-44cf-b2c5-962cee757d2c GET /v1/drugs/de815218-1776-44cf-b2c5-962cee757d2c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"H01BA",
"H01BA01"
],
"strength": null,
"pa_number": "PA1353/005/001",
"substances": [
"Argipressin"
],
"legal_basis": "Well-established use application (Article 10a of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "23/03/2018",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about vasopressin (argipressin).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.